2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-1-methyl-3-oxoindazole-4-carboxamide | 1421274-84-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-1-methyl-3-oxoindazole-4-carboxamide
• 英文别名: 2-[1-(4,4-difluorocyclohexyl)piperidin-4-yl]-1-methyl-3-oxoindazole-4-carboxamide
• CAS: 1421274-84-1
• 化学式: C₂₀H₂₆F₂N₄O₂
• 分子量: 392.449
• InChiKey: IMXAAXJRLKLQGB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  69.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-溴-6-碘苯甲酸 在 盐酸 、 indium(III) chloride 、 tris-(dibenzylideneacetone)dipalladium(0) 、 copper(l) iodide 、 乙醛肟 、 1,10-菲罗啉 、 草酰氯 、 sodium acetate 、 potassium carbonate 、 caesium carbonate 、 三乙胺 、 N,N-二异丙基乙胺 、 N,N-二甲基甲酰胺 、 tri tert-butylphosphoniumtetrafluoroborate 、 锌 作用下， 以 1,4-二氧六环 、 N-甲基吡咯烷酮 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 48.25h， 生成 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-1-methyl-3-oxoindazole-4-carboxamide
  参考文献：
  名称：

  [EN] 3-OXO-2,3-DIHYDRO-1H-INDAZOLE-4-CARBOXAMIDE DERIVATIVES AS PARP-1 INHIBITORS
  [FR] DÉRIVÉS DE 3-OXO-2,3-DIHYDRO-1H-INDAZOLE-4-CARBOXAMIDE UTILISÉS COMME INHIBITEURS DE LA PARP-1

  摘要：

  提供了3-氧代-2,3-二氢-1H-吲唑-4-羧酰胺衍生物，其选择性地抑制聚(ADP-核糖)聚合酶PARP-1的活性，而对聚(ADP-核糖)聚合酶PARP-2无影响。因此，本发明的化合物可用于治疗癌症、心血管疾病、中枢神经系统损伤和不同形式的炎症等疾病。本发明还提供了制备这些化合物的方法，包括这些化合物的制药组合物，以及利用包含这些化合物的制药组合物治疗疾病的方法。

  公开号：

  WO2013014038A1

文献信息

• 3-OXO-2,3-DIHYDRO-1H-INDAZOLE-4-CARBOXAMIDE DERIVATIVES AS PARP-1 INHIBITORS
  申请人：Papeo Gianluca Mariano Enrico

  公开号：US20140235675A1

  公开（公告）日：2014-08-21

  There are provided 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivatives which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1 with respect to poly (ADP-ribose) polymerase PARP-2. The compounds of this invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

  提供了3-氧代-2,3-二氢-1H-吲唑-4-羧酰胺衍生物，其能选择性地抑制聚(ADP-核糖)聚合酶PARP-1的活性，而对聚(ADP-核糖)聚合酶PARP-2无影响。因此，本发明的化合物可用于治疗癌症、心血管疾病、中枢神经系统损伤和不同形式的炎症等疾病。本发明还提供了制备这些化合物的方法、包含这些化合物的制药组合物以及利用包含这些化合物的制药组合物治疗疾病的方法。
• USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES
  申请人：DelMar Pharmaceuticals, Inc.

  公开号：US20180071244A1

  公开（公告）日：2018-03-15

  The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of malignancies of the central nervous system in pediatric patients, including glioblastoma multiforme (GBM) high grade glioma, and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N 7 methylation and that can induce double-stranded breaks in DNA. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents (e.g. cisplatin) and can possess additive or super-additive effects.
• USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER
  申请人：Bacha Jeffrey A.

  公开号：US20190091195A1

  公开（公告）日：2019-03-28

  Substituted hexitol derivatives such as dianhydrogalactitol are useful in the treatment of various neoplastic pathologies. Said pathologies include glioblastoma multiforme, non-small-cell lung carcinoma (NSCLC), ovarian cancer, and leptomeningeal carcinomatosis. The anti-neoplastic activity of dianhydrogalactitol is demonstrated to be due to its activity as an alkylating agent that creates N 7 methylation and inter-strand DNA crosslinks. The hexitol derivatives may be used alone or in combination with other anti-neoplastic agents.
• US9073893B2
  申请人：——

  公开号：US9073893B2

  公开（公告）日：2015-07-07
• [EN] USE OF DIANHYDROGALACTITOL OR DERIVATIVES AND ANALOGS THEREOF FOR TREATMENT OF NON-SMALL-CELL LUNG CARCINOMA, GLIOBLASTOMA, AND OVARIAN CARCINOMA BY INDUCTION OF DNA DAMAGE AND STALLING OF CELL CYCLE<br/>[FR] UTILISATION DE DIANHYDROGALACTITOL OU DE DÉRIVÉS ET D'ANALOGUES DE CELUI-CI POUR LE TRAITEMENT D'UN CARCINOME NON À PETITES CELLULES, D'UN GLIOBLASTOME ET D'UN CARCINOME DE L'OVAIRE PAR INDUCTION DE LÉSIONS DE L'ADN ET BLOCAGE DU CYCLE CELLULAIRE
  申请人：DEL MAR PHARMACEUTICALS

  公开号：WO2017042634A2

  公开（公告）日：2017-03-16

  The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma, non-small-cell lung carcinoma (NSCLC) and ovarian cancer, as well as other types of malignancy, including brain metastases of NSCLC. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation and inter-strand crosslinks that can induce double-stranded breaks in DNA. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents and can possess additive or synergistic effects. Dianhydrogalactitol can be used for treatment of leptomeningeal carcinomatosis.